BR112019003951A2 - métodos e composição para a predição da atividade de enzastaurina - Google Patents
métodos e composição para a predição da atividade de enzastaurinaInfo
- Publication number
- BR112019003951A2 BR112019003951A2 BR112019003951A BR112019003951A BR112019003951A2 BR 112019003951 A2 BR112019003951 A2 BR 112019003951A2 BR 112019003951 A BR112019003951 A BR 112019003951A BR 112019003951 A BR112019003951 A BR 112019003951A BR 112019003951 A2 BR112019003951 A2 BR 112019003951A2
- Authority
- BR
- Brazil
- Prior art keywords
- enzastaurin
- prediction
- activity
- composition
- methods
- Prior art date
Links
- AXRCEOKUDYDWLF-UHFFFAOYSA-N 3-(1-methyl-3-indolyl)-4-[1-[1-(2-pyridinylmethyl)-4-piperidinyl]-3-indolyl]pyrrole-2,5-dione Chemical compound C12=CC=CC=C2N(C)C=C1C(C(NC1=O)=O)=C1C(C1=CC=CC=C11)=CN1C(CC1)CCN1CC1=CC=CC=N1 AXRCEOKUDYDWLF-UHFFFAOYSA-N 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title abstract 2
- 229950002189 enzastaurin Drugs 0.000 title abstract 2
- 239000000090 biomarker Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medical Treatment And Welfare Office Work (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662382734P | 2016-09-01 | 2016-09-01 | |
| US201662414601P | 2016-10-28 | 2016-10-28 | |
| PCT/US2017/049747 WO2018045240A1 (en) | 2016-09-01 | 2017-08-31 | Methods and composition for the prediction of the activity of enzastaurin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019003951A2 true BR112019003951A2 (pt) | 2019-06-25 |
Family
ID=59923555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019003951A BR112019003951A2 (pt) | 2016-09-01 | 2017-08-31 | métodos e composição para a predição da atividade de enzastaurina |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11421280B2 (enExample) |
| EP (1) | EP3507384B1 (enExample) |
| JP (3) | JP7197915B2 (enExample) |
| KR (1) | KR20190046935A (enExample) |
| CN (1) | CN109952383B (enExample) |
| AU (1) | AU2017318669B2 (enExample) |
| BR (1) | BR112019003951A2 (enExample) |
| CA (1) | CA3035386A1 (enExample) |
| JO (1) | JOP20190025A1 (enExample) |
| MX (1) | MX2019002377A (enExample) |
| PH (1) | PH12019500422A1 (enExample) |
| RU (1) | RU2019109011A (enExample) |
| SG (2) | SG11201901762WA (enExample) |
| TW (2) | TW202313973A (enExample) |
| WO (1) | WO2018045240A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190025A1 (ar) | 2016-09-01 | 2019-02-19 | Denovo Biopharma Llc | طرق وتركيبة لتوقع نشاط إنزاستورين |
| CN110496223B (zh) * | 2018-05-17 | 2021-09-10 | 复旦大学附属肿瘤医院 | 一种治疗非霍奇金氏淋巴瘤的药物组合物 |
| EP3849559A4 (en) * | 2018-09-12 | 2022-06-01 | Denovo Biopharma LLC | COMBINATION OF ENZASTAURIN AND INHIBITORS OF BTK AND USES THEREOF |
| CN111549033B (zh) * | 2020-06-11 | 2021-02-12 | 南京市江宁医院 | 慢病毒感染人表皮角质细胞株及其构建方法和应用 |
| US11227690B1 (en) * | 2020-09-14 | 2022-01-18 | Opendna Ltd. | Machine learning prediction of therapy response |
| US20240321421A1 (en) * | 2021-07-23 | 2024-09-26 | Kaohsiung Medical University | Clinical therapeutic drug prediction and recommendation system and method for evaluating efficacy of second-generation hormone drug in treatment of prostate cancer |
| US20230131677A1 (en) * | 2021-10-21 | 2023-04-27 | Toyota Research Institute, Inc. | Systems and methods for predicting the effect of an intervention via machine learning |
| WO2023097197A2 (en) * | 2021-11-23 | 2023-06-01 | Denovo Biopharma Llc | Compositions and methods for assessing the efficacy of polynucleotide delivery and cancer therapy |
| US12474842B2 (en) * | 2021-12-13 | 2025-11-18 | Google Llc | Optimizing data placement based on data temperature and lifetime prediction |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE456367T1 (de) | 1993-12-23 | 2010-02-15 | Lilly Co Eli | Proteinkinase c inhibitoren |
| AU2001285047A1 (en) * | 2000-08-16 | 2002-02-25 | Chiron Corporation | Human genes and gene expression products |
| US20040072217A1 (en) | 2002-06-17 | 2004-04-15 | Affymetrix, Inc. | Methods of analysis of linkage disequilibrium |
| CA2393720C (en) | 2002-07-12 | 2010-09-14 | Eli Lilly And Company | Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride |
| US20080299125A1 (en) | 2006-06-05 | 2008-12-04 | Perlegen Sciences, Inc. | Genetic basis of treatment response in depression patients |
| JP2014506459A (ja) | 2011-01-31 | 2014-03-17 | デノボ バイオマーカーズ インコーポレイテッド | 薬理ゲノミクスバイオマーカーを発見するための方法 |
| CA2838207A1 (en) | 2011-06-08 | 2012-12-13 | Denovo Biopharma (Hangzhou) Ltd. Co. | Methods and compositions of predicting activity of retinoid x receptor modulator |
| JOP20190025A1 (ar) | 2016-09-01 | 2019-02-19 | Denovo Biopharma Llc | طرق وتركيبة لتوقع نشاط إنزاستورين |
-
2017
- 2017-06-16 JO JOP/2019/0025A patent/JOP20190025A1/ar unknown
- 2017-08-31 KR KR1020197009407A patent/KR20190046935A/ko not_active Ceased
- 2017-08-31 EP EP17771623.0A patent/EP3507384B1/en active Active
- 2017-08-31 US US16/327,788 patent/US11421280B2/en active Active
- 2017-08-31 RU RU2019109011A patent/RU2019109011A/ru unknown
- 2017-08-31 CA CA3035386A patent/CA3035386A1/en active Pending
- 2017-08-31 CN CN201780066737.5A patent/CN109952383B/zh active Active
- 2017-08-31 JP JP2019512609A patent/JP7197915B2/ja active Active
- 2017-08-31 MX MX2019002377A patent/MX2019002377A/es unknown
- 2017-08-31 SG SG11201901762WA patent/SG11201901762WA/en unknown
- 2017-08-31 TW TW111122709A patent/TW202313973A/zh unknown
- 2017-08-31 AU AU2017318669A patent/AU2017318669B2/en not_active Ceased
- 2017-08-31 BR BR112019003951A patent/BR112019003951A2/pt not_active IP Right Cessation
- 2017-08-31 WO PCT/US2017/049747 patent/WO2018045240A1/en not_active Ceased
- 2017-08-31 TW TW106129838A patent/TWI771317B/zh not_active IP Right Cessation
- 2017-08-31 SG SG10201912134TA patent/SG10201912134TA/en unknown
-
2019
- 2019-02-27 PH PH12019500422A patent/PH12019500422A1/en unknown
-
2020
- 2020-08-26 JP JP2020142358A patent/JP2020188816A/ja active Pending
-
2022
- 2022-08-18 US US17/820,772 patent/US20230074781A1/en not_active Abandoned
- 2022-09-16 JP JP2022148064A patent/JP2022173308A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP3507384A1 (en) | 2019-07-10 |
| CN109952383B (zh) | 2024-01-05 |
| JOP20190025A1 (ar) | 2019-02-19 |
| KR20190046935A (ko) | 2019-05-07 |
| CN109952383A (zh) | 2019-06-28 |
| WO2018045240A1 (en) | 2018-03-08 |
| SG10201912134TA (en) | 2020-02-27 |
| PH12019500422A1 (en) | 2019-05-27 |
| MX2019002377A (es) | 2019-09-05 |
| US20190233902A1 (en) | 2019-08-01 |
| SG11201901762WA (en) | 2019-03-28 |
| RU2019109011A (ru) | 2020-10-05 |
| JP2019528705A (ja) | 2019-10-17 |
| TWI771317B (zh) | 2022-07-21 |
| JP2020188816A (ja) | 2020-11-26 |
| US20230074781A1 (en) | 2023-03-09 |
| EP3507384B1 (en) | 2023-08-30 |
| CA3035386A1 (en) | 2018-03-08 |
| TW201812125A (zh) | 2018-04-01 |
| JP2022173308A (ja) | 2022-11-18 |
| US11421280B2 (en) | 2022-08-23 |
| RU2019109011A3 (enExample) | 2021-01-22 |
| AU2017318669A1 (en) | 2019-03-07 |
| TW202313973A (zh) | 2023-04-01 |
| AU2017318669B2 (en) | 2023-04-20 |
| JP7197915B2 (ja) | 2022-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019003951A2 (pt) | métodos e composição para a predição da atividade de enzastaurina | |
| CO2020002588A2 (es) | Composiciones que comprenden un inhibidor de shp2 y metodos para tratar el cáncer | |
| BR112018074978A2 (pt) | anticorpos para alfa-sinucleína e usos dos mesmos | |
| BR112017026467A2 (pt) | uso de exossomos para o tratamento de doença | |
| BR112019010646A2 (pt) | métodos de tratamento de condições inflamatórias | |
| EA201992131A1 (ru) | Высокоаффинные специфичные к mage-a1 tcr и их применение | |
| MX384141B (es) | Métodos para monitorear y terapias para usarse en tratar el cáncer. | |
| BR112018013853A2 (pt) | composições e métodos relacionados a sistemas celulares terapêuticos multimodais para indicações de câncer | |
| EA201500835A1 (ru) | Терапевтическая и диагностическая мишень для рака, включающая dll3-связывающие реагенты | |
| BR112017008045A2 (pt) | compostos como inibidores de nik | |
| BR112017007975A2 (pt) | composições e métodos para o tratamento de disfunção das glândulas meibomianas | |
| BR112016004305A2 (pt) | métodos diagnósticos e composições para tratamento de glioblastoma | |
| BR112019005328A2 (pt) | composição farmacêutica líquida | |
| MX2017010919A (es) | Proteina de union il-18 (il-18bp) y anticuerpos en enfermedades inflamatorias. | |
| BR112018071583A2 (pt) | métodos para determinar dpp3 e métodos terapêuticos | |
| MX391815B (es) | AGENTES DE iARN, COMPOSICIONES Y METODOS DE LOS MISMOS PARA USARSE EN EL TRATAMIENTO DE ENFERMEDADES ASOCIADAS CON TRANSTITERINA (TTR). | |
| BR112016006978A2 (pt) | inibidores de tirosina quinase de bruton | |
| BR112016012968A2 (pt) | Métodos e composições para o tratamento de condições associadas com o envelhecimento | |
| MX2017016134A (es) | Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad. | |
| EA201890891A1 (ru) | Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение | |
| PE20160192A1 (es) | Composiciones y metodo para tratar condiciones asociadas con el complemento | |
| BR112017007704A2 (pt) | derivados de pirazolopirimidina como inibidores de nik | |
| BR112015023074A2 (pt) | agentes de ligação-met e uso dos mesmos | |
| BR112016001781A2 (pt) | inibidores de rorc2 e métodos de uso dos mesmos | |
| BR112017007715A2 (pt) | derivados de tienopirimidina como inibidores de nik |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2738 DE 27-06-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |